EFFICACY OF TOLVAPTAN ON AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS IN LATE-STAGE CKD

被引：0
|
作者：
Hattanda, Fumihiko [1 ]
Makita, Minoru [1 ]
Takeda, Sayo [1 ]
Watanabe, Kanako [1 ]
Kawashima, Keisuke [1 ]
Kondo, Keiichi [1 ]
Ishikawa, Yozou [1 ]
Kusunoki, Yoshihiro [1 ]
Ishikawa, Yasunobu [1 ]
Nishio, Saori [1 ]
Atsumi, Tatsuya [1 ]
机构：
[1] Hokkaido Univ, Dept Med 2, Sapporo, Hokkaido, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP013
引用
收藏
页码：106 / 106
页数：1
相关论文
共 50 条
  • [41] TOLVAPTAN TREATMENT FOR THREE YEARS SIGNIFICANTLY IMPROVED RENAL PROGNOSIS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS
    Gkika, Vasiliki
    Louka, Michaela
    Evangelou, Eirini
    Vasileiou, Kyriaki
    Gkalitsiou, Dimitra
    Kanellopoulou, Konstantina
    Drakopoulos, Angelos
    Tigka, Eirini
    Tsagkatakis, Mihail
    Tsirpanlis, George
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I226 - I227
  • [42] Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan
    Francisco José Borrego Utiel
    Ana Isabel Morales García
    Aurora Polo Moyano
    Francisco Roca Oporto
    Enoc Merino García
    Rafael Esteban de la Rosa
    International Urology and Nephrology, 2023, 55 : 2629 - 2637
  • [43] Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan
    Utiel, Francisco Jose Borrego
    Garcia, Ana Isabel Morales
    Moyano, Aurora Polo
    Oporto, Francisco Roca
    Garcia, Enoc Merino
    de la Rosa, Rafael Esteban
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (10) : 2629 - 2637
  • [44] Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD)
    Shiho Makabe
    Toshio Mochizuki
    Michihiro Mitobe
    Yumi Aoyama
    Hiroshi Kataoka
    Ken Tsuchiya
    Kosaku Nitta
    Clinical and Experimental Nephrology, 2018, 22 : 1079 - 1087
  • [45] In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”
    Shigeo Horie
    Satoru Muto
    Clinical and Experimental Nephrology, 2016, 20 : 149 - 150
  • [46] In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease"
    Horie, Shigeo
    Muto, Satoru
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 149 - 150
  • [47] Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
    Sans-Atxer, Laia
    Torra, Roser
    Fernandez-Llama, Patricia
    CLINICAL KIDNEY JOURNAL, 2013, 6 (05) : 457 - 463
  • [48] Cerebrovascular Function in Early-Stage Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Steele, Cortney
    Oh, Ester
    Struemph, Taylor
    Farmer-Bailey, Heather
    Gitomer, Berenice Y.
    Chonchol, Michel
    Nowak, Kristen L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 155 - 156
  • [49] Extrarenal manifestations of autosomal dominant polycystic kidney disease (ADPKD)
    Harutyunyan, S.
    Andreeva, E.
    Savenkova, N.
    Larionova, V.
    Leviashvili, G.
    PEDIATRIC NEPHROLOGY, 2011, 26 (09) : 1691 - 1691
  • [50] Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Cadnapaphornchai, Melissa A.
    CURRENT HYPERTENSION REVIEWS, 2013, 9 (01) : 21 - 26
12345